Published in Nature on May 15, 1987
Enhancement by Poly-ICLC During HIV-1 Infection (Poly-ICLC) | NCT02071095
Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J (1991) 11.86
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A (1989) 11.76
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med (1992) 5.32
Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol (1995) 5.32
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol (1995) 5.18
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J (1996) 5.10
Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol (1990) 5.08
Two transcription factors, NF-kappa B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter. Proc Natl Acad Sci U S A (1988) 4.83
Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci U S A (1990) 4.61
Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol (1992) 4.36
Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol (1988) 4.33
Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A (1988) 4.33
Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J Virol (1989) 4.25
Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J (1989) 4.24
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A (1995) 4.16
Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J (1987) 4.14
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 4.11
Interferon response element of the human gene 6-16. EMBO J (1988) 4.11
Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter. EMBO J (1989) 4.10
A relational database of transcription factors. Nucleic Acids Res (1990) 4.03
RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol (1992) 4.03
Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci U S A (1988) 3.97
UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol (1989) 3.83
A discrete element 3' of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol Cell Biol (1988) 3.74
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J (1993) 3.74
Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. J Virol (1988) 3.69
A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol (1992) 3.63
Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev (1992) 3.60
NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J (1989) 3.58
Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol (2000) 3.48
Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc Natl Acad Sci U S A (1987) 3.47
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol (2000) 3.31
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol (1993) 3.27
Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res (1992) 3.22
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A (1991) 3.07
Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci U S A (1989) 3.00
Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1992) 2.93
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol (1995) 2.89
The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J (1992) 2.86
Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol (1992) 2.86
The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J (1987) 2.85
Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci U S A (1988) 2.79
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci U S A (1990) 2.75
Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J (1988) 2.74
Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A (1992) 2.72
Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci U S A (1987) 2.66
TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors. EMBO J (1989) 2.65
c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding. Mol Biol Cell (1992) 2.53
Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis. Proc Natl Acad Sci U S A (1989) 2.51
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
Activation of Rac1 by shear stress in endothelial cells mediates both cytoskeletal reorganization and effects on gene expression. EMBO J (2002) 2.46
Phorbol ester enhances human immunodeficiency virus-promoted gene expression and acts on a repeated 10-base-pair functional enhancer element. Mol Cell Biol (1987) 2.42
The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A (2000) 2.42
A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol (1997) 2.41
A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kappaB-dependent gene activity. EMBO J (2006) 2.41
Cytoplasmic retention, DNA binding and processing of the NF-kappa B p50 precursor are controlled by a small region in its C-terminus. EMBO J (1991) 2.39
NF-kappa B protein purification from bovine spleen: nucleotide stimulation and binding site specificity. Proc Natl Acad Sci U S A (1988) 2.39
Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol (1990) 2.34
The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol (1989) 2.32
Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med (1990) 2.28
Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol (1992) 2.26
An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation. Mol Cell Biol (1994) 2.26
A large protein containing zinc finger domains binds to related sequence elements in the enhancers of the class I major histocompatibility complex and kappa immunoglobulin genes. Mol Cell Biol (1990) 2.22
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol (1993) 2.20
Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci U S A (1991) 2.17
Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus transactivating region. Proc Natl Acad Sci U S A (1989) 2.17
A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res (2000) 2.16
In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. J Virol (1993) 2.15
Inhibition of transcription factors belonging to the rel/NF-kappa B family by a transdominant negative mutant. EMBO J (1991) 2.15
Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol (1989) 2.14
Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA. Proc Natl Acad Sci U S A (1989) 2.14
Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev (1996) 2.14
Transforming but not immortalizing oncogenes activate the transcription factor PEA1. EMBO J (1988) 2.14
Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12
Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci U S A (1994) 2.12
Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J (1995) 2.10
In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter. EMBO J (1987) 2.09
Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest (1991) 2.08
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell (1983) 25.46
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature (1970) 19.38
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
Immunoglobulin gene transcription is activated by downstream sequence elements. Cell (1983) 15.53
Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell (1986) 15.30
A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature (1986) 14.34
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
NF-kappa B: ten years after. Cell (1996) 12.80
Cloned poliovirus complementary DNA is infectious in mammalian cells. Science (1981) 12.50
Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A (1981) 12.00
Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion. Proc Natl Acad Sci U S A (1970) 11.83
Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell (1988) 11.62
NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell (1989) 11.19
The "initiator" as a transcription control element. Cell (1989) 11.13
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Polypeptide cleavages in the formation of poliovirus proteins. Proc Natl Acad Sci U S A (1968) 10.43
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature (1995) 10.36
The V(D)J recombination activating gene, RAG-1. Cell (1989) 9.79
Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region. Cell (1981) 9.54
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science (1990) 9.33
Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature (1990) 9.31
Further evidence on the formation of poliovirus proteins. J Mol Biol (1970) 9.29
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
A detailed model of reverse transcription and tests of crucial aspects. Cell (1979) 8.93
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci U S A (1982) 8.53
Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements. Cell (1985) 8.16
Covalent linkage of a protein to a defined nucleotide sequence at the 5'-terminus of virion and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci U S A (1977) 8.12
Identification of a ten-amino acid proline-rich SH3 binding site. Science (1993) 8.05
Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science (1987) 7.63
Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell (1995) 7.55
ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev (2000) 7.28
Defective viral particles and viral disease processes. Nature (1970) 7.24
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94
A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA. Cell (1990) 6.85
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 6.80
5'-terminal structure of poliovirus polyribosomal RNA is pUp. Proc Natl Acad Sci U S A (1976) 6.78
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (1980) 6.76
Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. Proc Natl Acad Sci U S A (1980) 6.73
Gene conversion: some implications for immunoglobulin genes. Cell (1981) 6.70
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Morphogenesis of poliovirus. I. Association of the viral RNA with coat protein. J Mol Biol (1968) 6.58
Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol (1990) 6.57
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell (1991) 6.48
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Modular binding domains in signal transduction proteins. Cell (1995) 6.34
Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev (1996) 6.32
Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes. Cell (1981) 6.31
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
Poliovirus RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA. EMBO J (1993) 6.29
The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev (1988) 6.23
RNA metabolism of murine leukemia virus: detection of virus-specific RNA sequences in infected and uninfected cells and identification of virus-specific messenger RNA. J Mol Biol (1973) 6.19
RNA-directed DNA synthesis and RNA tumor viruses. Adv Virus Res (1972) 6.11
Immunoglobulin synthesis by lymphoid cells transformed in vitro by Abelson murine leukemia virus. Cell (1979) 6.03
Ribonucleic acid synthesis of vesicular stomatitis virus. 3. Multiple complementary messenger RNA molecules. Virology (1970) 5.99
Aspects of the synthesis of poliovirus RNA and the formation of virus particles. Virology (1966) 5.85
Isolation and characterization of a mouse cDNA clone that expresses mast-cell growth-factor activity in monkey cells. Proc Natl Acad Sci U S A (1984) 5.81
In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of Moloney murine leukemia virus. Cell (1979) 5.78
Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature (1984) 5.75
Ribonucleic acid synthesis of vesicular stomatitis virus. I. Species of ribonucleic acid found in Chinese hamster ovary cells infected with plaque-forming and defective particles. J Virol (1969) 5.73
High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections. Cell (1978) 5.72
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev (1989) 5.61
Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3' ends. Cell (1980) 5.59
Primer requirement and template specificity of the DNA polymerase of RNA tumor viruses. Proc Natl Acad Sci U S A (1971) 5.55
The involvement of NF-kappa B in beta-interferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell (1989) 5.50
A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell (1990) 5.39
The mechanism of RNA recombination in poliovirus. Cell (1986) 5.35
Translation of MuLV and MSV RNAs in nuclease-treated reticulocyte extracts: enhancement of the gag-pol polypeptide with yeast suppressor tRNA. Cell (1978) 5.31
Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol (1985) 5.21
A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med (1976) 5.13
Poliovirus mutant that does not selectively inhibit host cell protein synthesis. Mol Cell Biol (1985) 4.94
An inhibitory domain of E12 transcription factor prevents DNA binding in E12 homodimers but not in E12 heterodimers. Cell (1991) 4.80
Transcriptional activation by Sp1 as directed through TATA or initiator: specific requirement for mammalian transcription factor IID. Proc Natl Acad Sci U S A (1990) 4.79
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med (1996) 4.79
Ordered transcription of RNA tumor virus genomes. J Mol Biol (1976) 4.78
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78
The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci U S A (1991) 4.66
Inhibition of translation by poliovirus: inactivation of a specific initiation factor. Proc Natl Acad Sci U S A (1978) 4.59
Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature (1990) 4.59
Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science (1992) 4.57
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature (1992) 4.46
Tumor viruses: 1974. Cold Spring Harb Symp Quant Biol (1975) 4.44
Retracted Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity (1999) 4.42
Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol (1991) 4.42
HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell (1989) 4.40
Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell (1997) 4.39
Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev (1995) 4.38
Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature (1999) 4.34
Expression of animal virus genomes. Bacteriol Rev (1971) 4.33
Purification and properties of poliovirus double-stranded ribonucleic acid. J Mol Biol (1966) 4.31
Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol (1993) 4.29